RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
67 hedge funds and large institutions have $542M invested in RAPT Therapeutics in 2020 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 21 increasing their positions, 16 reducing their positions, and 7 closing their positions.
186% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 7
63% more call options, than puts
Call options by funds: $820K | Put options by funds: $503K
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
31% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 16
24% more funds holding
Funds holding: 54 → 67 (+13)
22% more capital invested
Capital invested by funds: $443M → $542M (+$99.1M)
0.89% more ownership
Funds ownership: 7.71% → 8.6% (+0.89%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$33.2M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$16M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$11.5M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$6.66M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$5.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PS
Peter Svennilson
|
-$31.8M |
| 2 |
Squarepoint
New York
|
-$12.6M |
| 3 |
ROTUOC
Regents of the University of California
Oakland,
California
|
-$5.31M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$3.44M |
| 5 |
Goldman Sachs
New York
|
-$2.56M |
RAPT Hedge Fund Activity: Q3 2020 in Review
67 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q3 2020, worth a combined $542M — up 22% from $443M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new RAPT positions and 7 closed out — a net gain of 13 holders — while 21 added to existing stakes and 16 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $33.2M. The largest seller was Peter Svennilson, cutting an estimated $31.8M.
- 67 institutional investors held RAPT Therapeutics (RAPT) as of Q3 2020, up from 54 in Q2 2020.
- Funds reported $542M of RAPT Therapeutics stock for Q3 2020, up 22% quarter-over-quarter.
- 20 funds opened new RAPT Therapeutics positions in Q3 2020 and 7 closed out, a net change of +13 holders.
- The largest RAPT Therapeutics buyer in Q3 2020 was T. Rowe Price Associates, an estimated $33.2M added.
- The largest RAPT Therapeutics seller in Q3 2020 was Peter Svennilson, an estimated $31.8M sold.
Based on aggregated 13F filings for Q3 2020.